These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 21595277)
1. [Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus]. Toyonaga T; Araki E Nihon Rinsho; 2011 May; 69(5):890-4. PubMed ID: 21595277 [TBL] [Abstract][Full Text] [Related]
2. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?]. Kjeldsen R; Sandbaek A Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227 [TBL] [Abstract][Full Text] [Related]
3. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Wajcberg E; Tavaria A Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187 [TBL] [Abstract][Full Text] [Related]
4. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Kadowaki T; Namba M; Yamamura A; Sowa H; Wolka AM; Brodows RG Endocr J; 2009; 56(3):415-24. PubMed ID: 19194050 [TBL] [Abstract][Full Text] [Related]
5. [Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus]. Perusicová J Vnitr Lek; 2008 Apr; 54(4):377-86. PubMed ID: 18630617 [TBL] [Abstract][Full Text] [Related]
6. [Exenatide trials for the treatment of type 2 diabetes]. Fernández Landó L; Casellini CM Medicina (B Aires); 2009; 69(4):447-57. PubMed ID: 19770100 [TBL] [Abstract][Full Text] [Related]
7. Exenatide: a novel approach for treatment of type 2 diabetes. Mikhail N South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Tzefos M; Harris K; Brackett A Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377 [TBL] [Abstract][Full Text] [Related]
9. An update on exenatide, a novel therapeutic option for patients with type 2 diabetes. Crasto W; Khunti K; Davies MJ Drugs Today (Barc); 2011 Nov; 47(11):839-56. PubMed ID: 22146227 [TBL] [Abstract][Full Text] [Related]
10. Exenatide once weekly in type 2 diabetes. Scheen AJ Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642 [No Abstract] [Full Text] [Related]
11. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Gallwitz B Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672 [TBL] [Abstract][Full Text] [Related]
12. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Pinelli NR; Cha R; Brown MB; Jaber LA Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626 [TBL] [Abstract][Full Text] [Related]
13. Exenatide: its position in the treatment of type 2 diabetes. Guerci B; Martin CS Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126 [TBL] [Abstract][Full Text] [Related]
18. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Cvetković RS; Plosker GL Drugs; 2007; 67(6):935-54. PubMed ID: 17428109 [TBL] [Abstract][Full Text] [Related]
19. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Rosenstock J; Fonseca V Diabetes Care; 2007 Nov; 30(11):2972-3. PubMed ID: 17965313 [No Abstract] [Full Text] [Related]
20. Exenatide in combination therapy: small study, big market, and many unanswered questions. Malozowski S Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355 [No Abstract] [Full Text] [Related] [Next] [New Search]